Acquired amegakaryocytic thrombocytopenic purpura: a review of therapeutic options
Hematology/Oncology and Stem Cell Therapy
Acquired amegakaryocytic thrombocytopenic purpura (AATP) is a rare bone marrow disorder characterized by either a marked decrease or a complete absence of megakaryocytes with preservation of all other cell lines. More than 60 cases of AATP have been reported in literature thus far. Due to the rarity of this disease, no standard treatment guidelines have been established and therapy is based on a handful of case studies and expert opinion. Herein, we provide a comprehensive review on currently utilized therapeutic options for AATP.
Hussain, S. A., Zafar, A., Faisal, H., & Ud Din, M. A. (2023). Acquired amegakaryocytic thrombocytopenic purpura: a review of therapeutic options. Hematology/Oncology and Stem Cell Therapy, 16 (3), 291-302. https://doi.org/10.56875/2589-0646.1063